Prognostic significance of p63, p53 and ki67 expression in laryngeal basaloid squamous cell carcinomas. - Concepedia

Concepedia

Publication | Closed Access

Prognostic significance of p63, p53 and ki67 expression in laryngeal basaloid squamous cell carcinomas.

12

Citations

65

References

2011

Year

Semih Öncel, Burak Tatar

Abstract

To our knowledge, this is the first clinical study of p63 expression in laryngeal BSCC.

References

	Year	Citations
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Stephen B. Hanauer, Brian G. Feagan, Gary R. Lichtenstein, The Lancet InflammationChronic Inflammatory DiseasesAnti-inflammatoryMaintenance InfliximabGastroenterology	2002	4.1K
Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences Edward V. Loftus Gastroenterology InflammationChronic Inflammatory DiseasesEnvironmental InfluencesEpidemiologyFunctional Gastrointestinal Disorder	2004	3.1K
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis Brian G. Feagan, Paul Rutgeerts, Bruce E. Sands, New England Journal of Medicine	2013	2.8K
Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease Daniel H. Present, Paul Rutgeerts, Stephan Targan, New England Journal of Medicine	1999	2.7K
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial Jean–Frédéric Colombel, William J. Sandborn, Paul Rutgeerts, Gastroenterology Chronic Inflammatory DiseasesAutoimmune DiseaseImmunologyClinical TrialsGastroenterology	2006	2.2K
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease Bruce E. Sands, Frank Anderson, Çharles N. Bernstein, New England Journal of Medicine	2004	2.2K
Epidemiology and Natural History of Inflammatory Bowel Diseases Jacques Cosnes, Corinne Gower‐Rousseau, Philippe Seksik, Gastroenterology InflammationClinical EpidemiologyNatural HistoryGastroenterologyUlcerative Colitis	2011	2.1K
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease Brian G. Feagan, William J. Sandborn, Christopher Gasink, New England Journal of Medicine	2016	1.7K
Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial Stephen B. Hanauer, William J. Sandborn, Paul Rutgeerts, Gastroenterology InflammationChronic Inflammatory DiseasesAutoimmune DiseaseImmunologyPathology	2006	1.7K
Certolizumab Pegol for the Treatment of Crohn's Disease William J. Sandborn, Brian G. Feagan, S Stoĭnov, New England Journal of Medicine	2007	1.1K

Page 1